SENSEX
NIFTY
GOLD
USD/INR

Weather

image 29    C

National News

The Hindu Businessline

National / The Hindu Businessline

details

Piramal Pharma expects FY 2027 to see a revival in growth

It posted a Rs 9 crore loss Q4 FY 26, impacted by an impairment cost of Rs 176 crore linked to assets under development

29 Apr 2026 9:17 pm